PRNewsWire
25 Mar 2026, 13:00 UTC · 26w ago
Verdict
Headline leans bullish. We score RARE −1.00 across two claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Ultragenyx's Phase III Orbit and Cosmic studies for setrusumab failed to achieve statistical significance against primary endpoints for reduction in annualized clinical fracture rates.
So whatThe failure of two Phase III trials for a lead drug candidate typically represents a major loss of future revenue potential and a significant blow to the company's valuation.
More negative than 99% of claims this week
A class action securities lawsuit has been filed against Ultragenyx alleging that the company concealed material adverse facts regarding the efficacy and risks of setrusumab.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit following a 42% stock price drop after Phase III clinical trials failed to meet primary endpoints.
More negative than 86% of ticker scores this week
The company is under securities investigation after shares fell following a reported net loss.
More negative than 82% of ticker scores this week
The company reduced its full-year Adjusted EBITDA guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
7h ago
−20.6%
Price agrees with the score
$14.69 vs $18.50 close before publication (Mar 24) · not market-adjusted
RARE chart →
